Fiche centre
Uniwersyteckie Centrum Kliniczne
Gdansk — Poland
Essais liés19clinical trials
VilleGdansklocalisation
PaysPolandlocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06383390
Essais cliniques associés
19| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Maridebart cafraglutide | Insuffisance cardiaque | Phase 3 | NCT07037459 | MARITIME-HF — Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity | RECRUITING |
| Selatogrel | Maladie coronarienne | Phase 3 | NCT04957719 | SOS-AMI — Selatogrel Outcome Study in Suspected Acute Myocardial Infarction | ENROLLING_BY_INVITATION |
| Pumitamig | Cancer | Phase 3 | NCT07173751 | ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer | RECRUITING |
| Empagliflozin | Maladie rénale chronique | Phase 3 | NCT07107945 | A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) | ACTIVE_NOT_RECRUITING |
| Finerenone (Kerendia, BAY94-8862) | Maladie rénale chronique | Phase 3 | NCT05196035 | FIONA — A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria | ACTIVE_NOT_RECRUITING |
| Retatrutide | Maladie rénale chronique | Phase 3 | NCT06383390 | The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) | ACTIVE_NOT_RECRUITING |
| Soticlestat | Épilepsie | Phase 3 | NCT04940624 | A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome | COMPLETED |
| Soticlestat | Épilepsie | Phase 2 | NCT03635073 | Endymion 1 — A Study of Soticlestat in Adults and Children With Rare Epilepsies | TERMINATED |
| Soticlestat | Épilepsie | Phase 3 | NCT05163314 | A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome | TERMINATED |
| Soticlestat | Épilepsie | Phase 3 | NCT04938427 | A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome | COMPLETED |
| Amivantamab | Cancer | Phase 3 | NCT04538664 | PAPILLON — A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions | ACTIVE_NOT_RECRUITING |
| Erenumab Dose 1 | Migraine | Phase 3 | NCT03832998 | OASIS(CM) — Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine | COMPLETED |
| Trontinemab | Alzheimer | Phase 3 | NCT07170150 | TRONTIER 2 — A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease | ACTIVE_NOT_RECRUITING |
| Nipocalimab | Myasthénie | Phase 2/3 | NCT05265273 | A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis | RECRUITING |
| Satralizumab | Myopathies | Phase 2 | NCT06450639 | SHIELD DMD — A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD) | ACTIVE_NOT_RECRUITING |
| Obinutuzumab | Lupus | Phase 2 | NCT05039619 | POSTERITY — A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants | RECRUITING |
| Erenumab Dose 1 | Migraine | Phase 3 | NCT03836040 | OASIS(EM) — Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine | ACTIVE_NOT_RECRUITING |
| Efgartigimod IV | Myasthénie | Phase 2/3 | NCT04833894 | ADAPT Jr — Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING |
| Fenebrutinib | SEP | Phase 2 | NCT07161258 | FENerations1 — A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS) | RECRUITING |